Moderna : A confident management at the start of the year
>A consensus that looks cautious in our view - Yesterday we had an interview with Stéphane Bancel, CEO of Moderna, at the ODDO BHF Forum. This intervention following the approval of his Vaccine against COVID-19 in Europe was most reassuring. As underscored by Moderna's management, we believe that the mRNA vaccine will also protect against the various current mutations. Bear in mind that Moderna's vaccine expresses the complete Spike protein of the SARS-VOC-2 ...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.